Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-03-08

Clinical Trial Update: Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea

View source ↗

Summary

Post-marketing surveillance study assessing safety and efficacy of Inlyta in South Korea for advanced renal cell carcinoma; study completed with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • INLYTA (AXITINIB)

Snippet

Sponsor: Pfizer | Conditions: Advanced Renal Cell Carcinoma | Status: COMPLETED | Results posted: 2024-03-08